Generic placeholder image

Current Drug Delivery

Editor-in-Chief

ISSN (Print): 1567-2018
ISSN (Online): 1875-5704

Review Article

Novel Products as Promising Therapeutic Agents for Angiogenesis Inhibition

In Press, (this is not the final "Version of Record"). Available online 09 January, 2024
Author(s): Shaheen Sultana*, Shahnaz Sultana, Shehla Nasar Mir Najib Ullah and Ameeduzzafar Zafar
Published on: 09 January, 2024

DOI: 10.2174/0115672018277869231217165048

Price: $95

conference banner
Abstract

Objective: Angiogenesis is the process of forming new blood vessels from pre-existing vessels and occurs during development, wound healing, and tumor growth. In this review, we aimed to present a comprehensive view of various factors contributing to angiogenesis during carcinogenesis. Anti-angiogenesis agents prevent or slow down cancer growth by interrupting the nutrients and blood supply to the tumor cells, and thus can prove beneficial for treatment.

Method: The discovery of several novel angiogenic inhibitors has helped to reduce both morbidity and mortality from several life-threatening diseases, such as carcinomas. There is an urgent need for a new comprehensive treatment strategy combining novel anti-angiogenic agents for the control of cancer. The article contains details of various angiogenic inhibitors that have been adopted by scientists to formulate and optimize such systems in order to make them suitable for cancer.

Results: The results of several researches have been summarized in the article and all of the data support the claim that anti-angiogenic agent is beneficial for cancer treatment.

Conclusion: This review focuses on novel antiangiogenic agents that play a crucial role in controlling carcinogenesis.

Keywords: Angiogenesis, antiangiogenic agents, cancer, carcinogenesis, phytochemicals, Novel angiogenesis inhibitors


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy